| Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025 |
PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025. |
zacks.com |
2025-05-09 18:30:22 |
Czytaj oryginał (ang.) |
| Top 3 Health Care Stocks That Are Preparing To Pump This Quarter |
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. |
benzinga.com |
2025-05-09 11:16:56 |
Czytaj oryginał (ang.) |
| Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates |
Prothena (PRTA) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $1.34 per share a year ago. |
zacks.com |
2025-05-08 22:50:36 |
Czytaj oryginał (ang.) |
| Prothena Reports First Quarter 2025 Financial Results and Business Highlights |
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the first quarter of 2025 and provided business highlights. |
businesswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Prothena to Report First Quarter 2025 Financial Results on May 8 |
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. |
businesswire.com |
2025-05-01 20:05:00 |
Czytaj oryginał (ang.) |
| Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus |
PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter. |
zacks.com |
2025-02-21 16:50:26 |
Czytaj oryginał (ang.) |
| Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript |
Prothena Corporation plc (NASDAQ:PRTA ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Gene Kinney - President and Chief Executive Officer Chad Swanson - Chief Development Officer Tran Nguyen - Chief Financial Officer and Chief Strategy Officer Brandon Smith - Chief Operating Officer Conference Call Participants Emma Seymour - Piper Sandler Jay Olson - Oppenheimer Umer Raffat - Evercore Charles Duncan - Cantor Fitzgerald Jason Butler - Citizens JMP Michael Yee - Jefferies Rudy Li - Chardan Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Operator Good day, ladies and gentlemen, and welcome to the Prothena Biosciences Fourth Quarter and Full Year 2024 Financial Results Conference Call. My name is Pam, and I will be your coordinator for today. |
seekingalpha.com |
2025-02-20 22:45:53 |
Czytaj oryginał (ang.) |
| Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates |
Prothena (PRTA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $1.26 per share a year ago. |
zacks.com |
2025-02-20 20:25:26 |
Czytaj oryginał (ang.) |
| Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights |
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena reported financial results for the 4th quarter and full year 2024. The Company also provided business highlights and 2025 financial guidance. |
businesswire.com |
2025-02-20 18:05:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm |
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prothena Corporation PLC (NASDAQ: PRTA) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. |
globenewswire.com |
2025-02-17 20:10:00 |
Czytaj oryginał (ang.) |
| Prothena Announces Board of Directors Update |
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced that Oleg Nodelman will step down from Prothena's Board of Directors to create time to focus on existing and new endeavors. |
businesswire.com |
2024-12-30 18:05:00 |
Czytaj oryginał (ang.) |
| Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease |
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced results from PADOVA study conducted by partner Roche investigating prasinezumab in early-stage Parkinson's disease. |
businesswire.com |
2024-12-19 03:05:00 |
Czytaj oryginał (ang.) |
| Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report? |
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-12 14:36:18 |
Czytaj oryginał (ang.) |
| Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus |
PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter. |
zacks.com |
2024-11-13 10:51:11 |
Czytaj oryginał (ang.) |
| Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates |
Prothena (PRTA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to earnings of $0.38 per share a year ago. |
zacks.com |
2024-11-12 21:00:42 |
Czytaj oryginał (ang.) |
| Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts? |
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week. |
zacks.com |
2024-11-11 13:50:15 |
Czytaj oryginał (ang.) |
| Prothena to Report Third Quarter 2024 Financial Results on November 12 |
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its third quarter and first nine months of 2024 financial results on Tuesday, November 12, 2024. |
businesswire.com |
2024-11-05 18:05:00 |
Czytaj oryginał (ang.) |
| Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock? |
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-10-29 15:01:18 |
Czytaj oryginał (ang.) |
| Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength? |
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-10-29 07:50:29 |
Czytaj oryginał (ang.) |
| Prothena Announces Leadership Team Updates |
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer. |
businesswire.com |
2024-09-27 20:05:00 |
Czytaj oryginał (ang.) |
| What Makes Prothena (PRTA) a New Buy Stock |
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-08-19 17:01:05 |
Czytaj oryginał (ang.) |
| Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues |
Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY. |
zacks.com |
2024-08-09 14:21:08 |
Czytaj oryginał (ang.) |
| Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates |
Prothena (PRTA) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of a loss of $1.01 per share. This compares to loss of $1.03 per share a year ago. |
zacks.com |
2024-08-08 23:41:15 |
Czytaj oryginał (ang.) |
| Prothena to Report Second Quarter 2024 Financial Results on August 8 |
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its second quarter and first six months of 2024 financial results on Thursday, August 8, 2024. |
businesswire.com |
2024-08-01 20:05:00 |
Czytaj oryginał (ang.) |
| Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release |
Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-07-25 15:07:28 |
Czytaj oryginał (ang.) |
| Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last? |
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
zacks.com |
2024-06-24 13:50:36 |
Czytaj oryginał (ang.) |
| Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win |
Eli Lilly stock reversed premarket gains at the open Tuesday after an FDA panel endorsed its Alzheimer's treatment, donanemab. |
investors.com |
2024-06-11 16:20:35 |
Czytaj oryginał (ang.) |
| Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report? |
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-06-07 16:36:18 |
Czytaj oryginał (ang.) |
| Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate |
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases. |
zacks.com |
2024-05-29 15:31:07 |
Czytaj oryginał (ang.) |
| Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration |
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million. |
businesswire.com |
2024-05-28 20:05:00 |
Czytaj oryginał (ang.) |